Efficacy and safety of lowdose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism
: a randomized, multicenter, controlled trial.
Evaluation of serum endothelial cell specific molecule-1 (endocan) levels as a biomarker in patients with pulmonary thromboembolism
. Blood Coagul Fibrinolysis.
Quantification of lung perfusion blood volume with dual-energy CT: assessment of the severity of acute pulmonary thromboembolism
. AJR Am J Roentgenol 2014; 203:287-291.
The exact causes of many CA cases are unknown, and the rate of survival is still low.[sup] Venous thromboembolism has a high incidence in the world.[sup], Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1000 individuals in the population.[sup] Thrombosis from the deep venous system could block the pulmonary artery which leads to very serious consequences, especially high-risk pulmonary thromboembolism
(PTE) which is an important reason for CA.[sup], It may contribute to 8–13% of unexplained CA cases,[sup], which may be potentially reversible processes.[sup]
Intimal sarcoma of the pulmonary artery: a differential diagnosis of chronic pulmonary thromboembolism
. J Bras Pneumol.
4 out of 102 cases had pulmonary thromboembolism
Virchow's Triad preliminarily revealed the internal relationships between coagulant function abnormality and pathological changes in the vessel wall, based on venous thrombosis, which is the initial event of pulmonary thromboembolism
. Focusing on a molecular and cellular view, contemporary research reveals that the function of coagulation involving vascular endothelium in PTE is affected by hypoxia or inflammation, and developing an efficient test for the diagnosis and prognosis of PTE depends on the knowledge of the balance between prothrombotic and antithrombotic factors in the lung.
The angiographic pattern of arteritic lesions seems to be the same as that observed in pulmonary thromboembolism
. Also, it must be emphasized that pulmonary embolism due to flow limit of PA has been documented in these patients.
In these cases, a clinical presentation similar to acute pulmonary thromboembolism
with coughing, hemoptysis, and chest pain develops .
Several different methods to treat intracardiac thrombus formation and pulmonary thromboembolism
previously have been described: IV heparin, rTPA, thrombectomy, and extracorporeal membrane oxygenation (ECMO).
We describe a case report of a pulmonary thromboembolism
in a 57 year old woman who was diagnosed of hypertension for the past 12 years and a uterine fibroid diagnosed about 2 years prior to her demise in a non-smoking female with no history of malignancy or hormone use.
Bayer HealthCare announced today the approval in Japan of its oral Factor Xa inhibitor Xarelto (rivaroxaban) for the treatment and secondary prevention of pulmonary thromboembolism
and deep vein thrombosis by the Japanese Ministry of Health, Labor and Welfare (MHLW).